bleeding risk

13 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Cardiology

Multilevel Stewardship to Optimize Antithrombotic Therapy in DOAC Users: Lessons from a Veterans Health Initiative

By MedXY|Jun 25, 2026

A multicomponent stewardship intervention significantly reduced inappropriate antiplatelet prescription among patients on DOACs, decreasing bleeding risk, particularly in stable coronary artery disease.

Cardiology

bleeding risk

Latest news

Multilevel Stewardship to Optimize Antithrombotic Therapy in DOAC Users: Lessons from a Veterans Health Initiative

Pre-Treatment Fibrin Clot Lysis Time Predicts Bleeding Risk in Atrial Fibrillation Patients on Oral Anticoagulants

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

NSAID Co-prescription in Atrial Fibrillation: Doubling the Bleeding Burden Across All Oral Anticoagulants

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

Aspirin in the Healthy Elderly: ASPREE’s Clear Message — No Benefit, Higher Bleeding, and Unexpected Cancer Signal

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

Evaluating Aspirin-Free Therapy Versus Dual Antiplatelet Treatment Post-Coronary Stenting: Insights from the STOPDAPT-3 Trial

Evaluating the Adjuvant Role of Low-Dose Aspirin in Cancer-Associated Venous Thromboembolism: Efficacy, Safety, and Clinical Implications

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy